Evidence map›Paper›PMID 37064137›Full record

ArticleFrontiers in oncology2023

Genomic landscape and survival analysis of ctDNA "neo-

Chiara Nicolazzo, Valentina Magri, Luca Marino, Francesca Belardinilli, Federica Di Nicolantonio, Gianluigi De Renzi, Salvatore Caponnetto, Michela De Meo, Giuseppe Giannini, Daniele Santini and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06440902 (Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06440902 phase2recruitingnot on this map

Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA: an Open, Prospective, Phase II Study

TypeinterventionalSponsorFudan UniversityRan2023 to 2028Enrolled1,100ConditionsColorectal Cancer MetastaticArmsCetuximab
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Chiara NicolazzoLab. Liquid Biopsy, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Valentina MagriDepartment of Radiology, Oncology and Pathology, Sapienza University, Rome, Italy.
Luca MarinoDepartment of Mechanical and Aerospace Engineering, Sapienza University of Rome, Rome, Italy.
Francesca BelardinilliLab. Liquid Biopsy, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Federica Di NicolantonioDepartment of Oncology, University of Torino, Candiolo, Italy.
Gianluigi De RenziLab. Liquid Biopsy, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Salvatore CaponnettoDepartment of Radiology, Oncology and Pathology, Sapienza University, Rome, Italy.
Michela De MeoLab. Liquid Biopsy, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Giuseppe GianniniLab. Liquid Biopsy, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Daniele SantiniDepartment of Radiology, Oncology and Pathology, Sapienza University, Rome, Italy.
Enrico CortesiDepartment of Radiology, Oncology and Pathology, Sapienza University, Rome, Italy.
Paola GazzanigaLab. Liquid Biopsy, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The term "neo- Patients and methods: 70 patients with stage IV Results: The most commonly detected actionable mutations in "neo- Conclusions: De-novo-targetable mutations occured in a large percentage of "neo-

Indexed as

bevacizumabcirculating tumor DNAneo-RASRAS mutant colorectal cancersurvival

Identifiers

PMID37064137
PMCPMC10093715
OpenAlexW4361293906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.